Astellas Pharma Inc. Company Analysis & Research
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company is a specialty international pharmaceutical company focused on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases.
The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Astellas is experiencing strong global sales trends of XTANDI for prostate cancer and BETANIS/MYRBETRIQ/BETMIGA for overactive bladder.
Company Overview
Founded: 1923. Headquarters: Chuo, Japan. Revenue: $13.4B. Market Cap: $28.9B. Ticker: 4503 (TSE).
Industry
Pharmaceutical Manufacturing - General
Cyborg Score: 6/10 — Solid
Trading at 56.1% below estimate of fair value, but faces long-term revenue headwinds from patent expirations and competitive pressures.
The company has shifted back into profit on a trailing twelve month basis with net income of ¥322.9b compared to a loss of ¥57.4b a year ago, supported by three straight quarters of positive EPS in 2026. However, bears argue that revenue is forecast to decline about 5% per year over the next three years alongside a five year earnings decline rate of 6.6% a year.
Key Strategic Insights for Astellas Pharma Inc.
- Strong global sales momentum in flagship drugs XTANDI and BETANIS/MYRBETRIQ/BETMIGA driving upward forecast revisions
- Trading on trailing P/E of 13.4x versus peer average of 19.5x and industry average of 16.5x, suggesting potential valuation discount
- Divergence between recent strong quarterly revenue (¥505.8b-¥571.2b) and three-year forecasts predicting 5% annual decline creates key investment tension
- Core oncology portfolio includes XTANDI, XOSPATA, PADCEV with expansion into adjacent therapeutic areas including ophthalmology and women's health
Recent Developments
- (February 2026) Announced upward revisions to consolidated financial forecast for FY2025 ending March 31, 2026
- (Q3 2026) Posted revenue of ¥571.2 billion and basic EPS of ¥56.04
- (September 2025) Joint Venture with Cell Therapy Manufacturing Platform (Astellas Pharma / Yaskawa Electric)
Competitors & Competitive Landscape
- Novartis — Immunology and rare disease focus
- Roche — Oncology and diagnostics leader
- Pfizer — Large cap diversified pharma
- Biogen — Neurology and immunology specialist
One of Astellas Pharma's 64 competitors is Novartis, a Corporation company based in Basel, Switzerland. Loss of exclusivity for major drugs and persistent R&D challenges threaten future revenue stability, while pricing pressures, regulatory risks, and supply chain complexities increase margin volatility across key global markets.
More Company Research
Unitronics (1989) (R"G) Ltd Audinate Group Limited Bakkt Holdings, Inc. Stabilus SE Newsmax IndiaMART InterMESH Limited Skyward Specialty Insurance Group Blackbaud, Inc. Koninklijke KPN N.V. Sealed Air Corporation Grupo Aeroportuario del Sureste, S.A.B. de C.V. Indian Railway Finance Corporation Limited Strategy Inc PT Pollux Properties Indonesia Tbk IT Link SAFull Company Research Reports
Looking for a more in-depth analysis of Astellas Pharma Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, analyst debate audio, and saved-company audio playlists.